Patient acceptance Nordiject new drug delivery system growth hormone Twenty-seven children years growth retardation open study acceptability new injection pen Nordiject Novo Nordisk A/S administration recombinant human growth hormone r-hGH study patients treatment r-hGH administered syringes vials experiences conventional technique comparison Nordiject injection pen replaceable needle cartridge IU r-hGH IU/mL benzyl solution solvent reconstitution pen doses IU injection regulation turning movement patients problems dissolving procedure pen two-thirds patients injection pain pen syringe Special attention local tolerability good thigh preferred injection site residual contents cartridges patients microbial contamination Contamination cartridge repeated test simplification injection procedure injection pen patients able injections active role treatment patients conventional syringes pen patients device 